Duration of untreated illness and duration of illness in anxiety disorders: assessment and influence on outcome.

Modern trends in pharmacopsychiatry Pub Date : 2013-01-01 Epub Date: 2013-09-20 DOI:10.1159/000351950
A Carlo Altamura, Giulia Camuri, Bernardo Dell'Osso
{"title":"Duration of untreated illness and duration of illness in anxiety disorders: assessment and influence on outcome.","authors":"A Carlo Altamura,&nbsp;Giulia Camuri,&nbsp;Bernardo Dell'Osso","doi":"10.1159/000351950","DOIUrl":null,"url":null,"abstract":"<p><p>Anxiety disorders are disabling and generally chronic conditions, with a lifetime prevalence of 15-20% in the general population. These disorders are usually associated with early onset and often remain untreated for several years with important consequences on patients' functioning and quality of life. From this perspective, recent literature has considered duration of illness (DI) and duration of untreated illness (DUI), two important variables influencing outcome in many psychiatric conditions including anxiety disorders. The DUI has been defined as the interval between the onset of a specific psychiatric disorder and the subsequent administration of the first adequate pharmacological treatment given at standard dosages and for an adequate period of time in compliant subjects. The DI can be defined as the time elapsing between the onset of a psychiatric disorder and the recovery from the illness. The two variables are likely interrelated, with a longer DUI being a major contributor to a longer DI. A significant body of evidence has shown that prolonged DI and DUI are associated with structural and functional brain abnormalities as well as with poor treatment response, particularly in schizophrenia. More recently, an increasing number of studies have been pointing toward a similar conclusion in affective disorders. As a consequence, the assessment of the latency to treatment (DUI) may represent one of the first steps in order to plan early interventions and reduce the overall DI. The present chapter highlights the role of the DI and latency to treatment in anxiety disorders, focusing on epidemiologic, neuropathological, clinical and prognostic issues. </p>","PeriodicalId":74212,"journal":{"name":"Modern trends in pharmacopsychiatry","volume":"29 ","pages":"111-8"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000351950","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern trends in pharmacopsychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000351950","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/9/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 15

Abstract

Anxiety disorders are disabling and generally chronic conditions, with a lifetime prevalence of 15-20% in the general population. These disorders are usually associated with early onset and often remain untreated for several years with important consequences on patients' functioning and quality of life. From this perspective, recent literature has considered duration of illness (DI) and duration of untreated illness (DUI), two important variables influencing outcome in many psychiatric conditions including anxiety disorders. The DUI has been defined as the interval between the onset of a specific psychiatric disorder and the subsequent administration of the first adequate pharmacological treatment given at standard dosages and for an adequate period of time in compliant subjects. The DI can be defined as the time elapsing between the onset of a psychiatric disorder and the recovery from the illness. The two variables are likely interrelated, with a longer DUI being a major contributor to a longer DI. A significant body of evidence has shown that prolonged DI and DUI are associated with structural and functional brain abnormalities as well as with poor treatment response, particularly in schizophrenia. More recently, an increasing number of studies have been pointing toward a similar conclusion in affective disorders. As a consequence, the assessment of the latency to treatment (DUI) may represent one of the first steps in order to plan early interventions and reduce the overall DI. The present chapter highlights the role of the DI and latency to treatment in anxiety disorders, focusing on epidemiologic, neuropathological, clinical and prognostic issues.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
焦虑症中未治疗的疾病持续时间和疾病持续时间:评估及其对结果的影响。
焦虑症是致残的,通常是慢性疾病,在一般人群中终生患病率为15-20%。这些疾病通常与早期发病有关,并且往往在数年内得不到治疗,对患者的功能和生活质量产生重要影响。从这个角度来看,最近的文献考虑了疾病持续时间(DI)和未治疗疾病持续时间(DUI),这是影响包括焦虑症在内的许多精神疾病结局的两个重要变量。DUI被定义为一种特定精神障碍的发作和随后在依从性受试者中给予标准剂量和适当时间的第一次适当药物治疗之间的间隔。残障期可以定义为从精神疾病发病到从疾病恢复之间的时间。这两个变量可能是相互关联的,较长的DUI是较长的DI的主要贡献者。大量证据表明,长期酒后饮酒和酒后驾车与大脑结构和功能异常以及治疗效果差有关,尤其是精神分裂症。最近,越来越多的研究在情感障碍方面也得出了类似的结论。因此,评估治疗潜伏期(DUI)可能是计划早期干预和减少总体DI的第一步。本章重点介绍了焦虑障碍治疗中DI和潜伏期的作用,重点介绍了流行病学、神经病理学、临床和预后问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders. The Link between Refractoriness and Neuroprogression in Treatment-Resistant Bipolar Disorder. The Contribution of Adult Hippocampal Neurogenesis to the Progression of Psychiatric Disorders. Neurodegeneration, Neuroregeneration, and Neuroprotection in Psychiatric Disorders. Pharmacological and Nonpharmacological Interventions to Arrest Neuroprogression in Psychiatric Disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1